Abstract
The paradigm for combined small-cell lung carcinoma (C-SCLC) is according to standard SCLC treatment with poor outcomes. The efficacy of immune checkpoint inhibitor (ICI) monotherapy for pretreated SCLC is still limited. Clinical researches exploring radiotherapy combined with immunotherapy showed promising synergistic effects in several tumors. We report one C-SCLC case after resistant to comprehensive treatment receiving nivolumab combined with radiotherapy achieving clinical complete remission (CCR). The combination module of ICI and radiation could be an option for relapsed C-SCLC, and the prognostic indicators need further research.
Plain language summary
Combined small-cell lung carcinoma (C-SCLC) is a rare type of lung cancer that shows more than two types of mixed pathology within the same tumor with poor outcomes. The treatment regimen is a combination of surgery, chemotherapy, radiotherapy and immunotherapy. Clinical research exploring radiotherapy combined with immunotherapy showed promising synergistic effects in several tumors excluding C-SCLC. In the present case, we used immunotherapy and radiotherapy as salvage treatments for a pretreated C-SCLC patient and achieved clinical complete remission. We analyzed some biomarkers of the patient, to explain the mechanisms of efficacy for immunotherapy combined with radiotherapy. The module of immunotherapy combined with radiotherapy may provide a new option for the treatment of C-SCLC.
References
- 1. . Combined SCLC clinical and pathologic characteristics. Clin. Lung Cancer 14(2), 113–119 (2013).
- 2. . The prognostic significance of histopathologic subtyping of small cell carcinoma of the lung according to the classification of the World Health Organization. A study of 375 consecutive patients. Cancer 52(11), 2144–2150 (1983).
- 3. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212), 1929–1939 (2019).
- 4. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J. Thorac. Oncol. 14(2), 237–244 (2019).
- 5. The role of immune microenvironment in small-cell lung cancer: distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. Eur. J. Cancer 101, 191–200 (2018).
- 6. . Complementing the cancer-immunity cycle. Front. Immunol. 10, 774 (2019).
- 7. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir. Med. 9(5), 467–475 (2021).
- 8. Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses. Cancer immunol. res. 7(12), 1903–1909 (2019).
- 9. . Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. Curr. Opin. Oncol. 27(6), 445–451 (2015).
- 10. . Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat. Rev. Clin. Oncol. 13(8), 516–524 (2016).
- 11. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur. J. Cancer 66, 91–94 (2016).
- 12. . The abscopal effect exists in non-small cell lung cancer: a case report and review of the literature. Cureus 11(2), e4118 (2019).
- 13. Abscopal benefits of localized radiotherapy depend on activated T-cell trafficking and distribution between metastatic lesions. Cancer Res. 76(5), 1009–1018 (2016).
- 14. Abscopal effect induced by modulated radiation therapy and pembrolizumab in a patient with pancreatic metastatic lung squamous cell carcinoma. Thorac. Cancer 11(7), 2014–2017 (2020).
- 15. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur. J. Cancer 109, 21–27 (2019).
